215 related articles for article (PubMed ID: 15946626)
1. Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(3):142-4. PubMed ID: 15946626
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
Rossi RE; Monasterolo G
Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children.
Tripodi S; Di Rienzo Businco A; Benincori N; Scala G; Pingitore G
Int Arch Allergy Immunol; 2006; 139(2):149-52. PubMed ID: 16374025
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
[TBL] [Abstract][Full Text] [Related]
6. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
Esch RE; Bush RK; Peden D; Lockey RF
Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen.
Agostinis F; Foglia C; Bruno ME; Falagiani P
Eur Ann Allergy Clin Immunol; 2009 Dec; 41(6):177-80. PubMed ID: 20128231
[TBL] [Abstract][Full Text] [Related]
8. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
9. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis.
Wilson DR; Lima MT; Durham SR
Allergy; 2005 Jan; 60(1):4-12. PubMed ID: 15575924
[TBL] [Abstract][Full Text] [Related]
10. Monoid sublingual immunotherapy.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
[TBL] [Abstract][Full Text] [Related]
11. Safety of sublingual immunotherapy started during the pollen season.
Ariano R; Incorvaia C; La Grutta S; Marcucci F; Pajno G; Sensi L; Di Cara G; Sieber J; Yacoub MR; Frati F
Curr Med Res Opin; 2009 Jan; 25(1):103-7. PubMed ID: 19210143
[TBL] [Abstract][Full Text] [Related]
12. Practice parameters for sublingual immunotherapy.
Ortolani C; Agostinis F; Amoroso S; Ariano R; Barbato A; Bassi M; Cadario G; Campi P; Cardinale F; Ciprandi G; D'Anneo R; Di Gioacchino M; Di Rienzo V; Fiocchi A; Galimberti M; Galli E; Giovannini M; Incorvaia C; La Grutta S; Lombardi C; Marcucci F; Marseglia G; Minelli M; Musarra A; Nettis E; Novembre E; Pajno G; Patriarca G; Pezzuto F; Piras P; Pucci S; Romano A; Romano C; Quercia O; Scala G; Schiavino D; Senna G; Sforza G; Tosca M; Tripodi S; Frati F
Monaldi Arch Chest Dis; 2006 Mar; 65(1):44-6. PubMed ID: 16700194
[TBL] [Abstract][Full Text] [Related]
13. Sublingual immunotherapy for allergic rhinitis.
Wilson DR; Torres LI; Durham SR
Cochrane Database Syst Rev; 2003; (2):CD002893. PubMed ID: 12804442
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules - IPD meta-analysis.
Sieber J; Köberlein J; Mösges R
Curr Med Res Opin; 2010 Apr; 26(4):925-32. PubMed ID: 20163297
[TBL] [Abstract][Full Text] [Related]
15. Rush sublingual immunotherapy in Parietaria allergic patients.
D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
Bahceciler NN; Cobanoglu N
Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
[TBL] [Abstract][Full Text] [Related]
18. Sublingual immunotherapy.
Lin SY; Leatherman B
Otolaryngol Clin North Am; 2011 Jun; 44(3):753-64, x-xi. PubMed ID: 21621059
[TBL] [Abstract][Full Text] [Related]
19. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Mösges R; Ritter B; Kayoko G; Allekotte S
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life.
De Castro G; Zicari AM; Indinnimeo L; Tancredi G; di Coste A; Occasi F; Castagna G; Giancane G; Duse M
Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2225-31. PubMed ID: 23893190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
